126 related articles for article (PubMed ID: 28238854)
1. Use of a probabilistic PBPK/PD model to calculate Data Derived Extrapolation Factors for chlorpyrifos.
Poet TS; Timchalk C; Bartels MJ; Smith JN; McDougal R; Juberg DR; Price PS
Regul Toxicol Pharmacol; 2017 Jun; 86():59-73. PubMed ID: 28238854
[TBL] [Abstract][Full Text] [Related]
2. A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans.
Timchalk C; Nolan RJ; Mendrala AL; Dittenber DA; Brzak KA; Mattsson JL
Toxicol Sci; 2002 Mar; 66(1):34-53. PubMed ID: 11861971
[TBL] [Abstract][Full Text] [Related]
3. An age-dependent physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus insecticide chlorpyrifos in the preweanling rat.
Timchalk C; Kousba AA; Poet TS
Toxicol Sci; 2007 Aug; 98(2):348-65. PubMed ID: 17504771
[TBL] [Abstract][Full Text] [Related]
4. Development of a source-to-outcome model for dietary exposures to insecticide residues: an example using chlorpyrifos.
Hinderliter PM; Price PS; Bartels MJ; Timchalk C; Poet TS
Regul Toxicol Pharmacol; 2011 Oct; 61(1):82-92. PubMed ID: 21722690
[TBL] [Abstract][Full Text] [Related]
5. Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat.
Timchalk C; Poet TS
Neurotoxicology; 2008 May; 29(3):428-43. PubMed ID: 18394709
[TBL] [Abstract][Full Text] [Related]
6. Derivation of human Biomonitoring Guidance Values for chlorpyrifos using a physiologically based pharmacokinetic and pharmacodynamic model of cholinesterase inhibition.
Arnold SM; Morriss A; Velovitch J; Juberg D; Burns CJ; Bartels M; Aggarwal M; Poet T; Hays S; Price P
Regul Toxicol Pharmacol; 2015 Mar; 71(2):235-43. PubMed ID: 25543108
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion.
Foxenberg RJ; Ellison CA; Knaak JB; Ma C; Olson JR
Toxicology; 2011 Jul; 285(1-2):57-66. PubMed ID: 21514354
[TBL] [Abstract][Full Text] [Related]
8. Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model.
Timchalk C; Kousba A; Poet TS
Toxicol Lett; 2002 Sep; 135(1-2):51-9. PubMed ID: 12243863
[TBL] [Abstract][Full Text] [Related]
9. Chlorpyrifos PBPK/PD model for multiple routes of exposure.
Poet TS; Timchalk C; Hotchkiss JA; Bartels MJ
Xenobiotica; 2014 Oct; 44(10):868-81. PubMed ID: 24839995
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of chlorpyrifos in adult male Long-Evans rats following repeated subcutaneous exposure to chlorpyrifos.
Ellison CA; Smith JN; Lein PJ; Olson JR
Toxicology; 2011 Sep; 287(1-3):137-44. PubMed ID: 21708215
[TBL] [Abstract][Full Text] [Related]
11. Age-dependent pharmacokinetic and pharmacodynamic response in preweanling rats following oral exposure to the organophosphorus insecticide chlorpyrifos.
Timchalk C; Poet TS; Kousba AA
Toxicology; 2006 Mar; 220(1):13-25. PubMed ID: 16343727
[TBL] [Abstract][Full Text] [Related]
12. Cholinesterase inhibition in chlorpyrifos workers: Characterization of biomarkers of exposure and response in relation to urinary TCPy.
Garabrant DH; Aylward LL; Berent S; Chen Q; Timchalk C; Burns CJ; Hays SM; Albers JW
J Expo Sci Environ Epidemiol; 2009 Nov; 19(7):634-42. PubMed ID: 18716607
[TBL] [Abstract][Full Text] [Related]
13. Effect of in vivo nicotine exposure on chlorpyrifos pharmacokinetics and pharmacodynamics in rats.
Lee S; Poet TS; Smith JN; Busby-Hjerpe AL; Timchalk C
Chem Biol Interact; 2010 Mar; 184(3):449-57. PubMed ID: 20097188
[TBL] [Abstract][Full Text] [Related]
14. A human life-stage physiologically based pharmacokinetic and pharmacodynamic model for chlorpyrifos: development and validation.
Smith JN; Hinderliter PM; Timchalk C; Bartels MJ; Poet TS
Regul Toxicol Pharmacol; 2014 Aug; 69(3):580-97. PubMed ID: 24200834
[TBL] [Abstract][Full Text] [Related]
15. A Novel Method for the Development of Environmental Public Health Indicators and Benchmark Dose Estimation Using a Health-Based End Point for Chlorpyrifos.
Zurlinden TJ; Reisfeld B
Environ Health Perspect; 2018 Apr; 126(4):047009. PubMed ID: 29681141
[TBL] [Abstract][Full Text] [Related]
16. Cholinesterase inhibition and toxicokinetics in immature and adult rats after acute or repeated exposures to chlorpyrifos or chlorpyrifos-oxon.
Marty MS; Andrus AK; Bell MP; Passage JK; Perala AW; Brzak KA; Bartels MJ; Beck MJ; Juberg DR
Regul Toxicol Pharmacol; 2012 Jul; 63(2):209-24. PubMed ID: 22504667
[TBL] [Abstract][Full Text] [Related]
17. Using physiologically-based pharmacokinetic models to incorporate chemical and non-chemical stressors into cumulative risk assessment: a case study of pesticide exposures.
Wason SC; Smith TJ; Perry MJ; Levy JI
Int J Environ Res Public Health; 2012 May; 9(5):1971-83. PubMed ID: 22754485
[TBL] [Abstract][Full Text] [Related]
18. Inter-individual variation in chlorpyrifos toxicokinetics characterized by physiologically based kinetic (PBK) and Monte Carlo simulation comparing human liver microsome and Supersome
Zhao S; Wesseling S; Rietjens IMCM; Strikwold M
Arch Toxicol; 2022 May; 96(5):1387-1409. PubMed ID: 35294598
[TBL] [Abstract][Full Text] [Related]
19. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
Yoon M; Kedderis GL; Yan GZ; Clewell HJ
Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
[TBL] [Abstract][Full Text] [Related]
20. Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat.
Smith JN; Campbell JA; Busby-Hjerpe AL; Lee S; Poet TS; Barr DB; Timchalk C
Toxicology; 2009 Jun; 261(1-2):47-58. PubMed ID: 19397948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
